All News

PSA2L.jpg

An Old Friend – Methotrexate in Psoriatic Arthritis

d Pedro Castillo

Methotrexate (MTX) remains one of our most used and reliable tools against a variety of rheumatic diseases, including PsA. When the time comes, as it often does, to escalate from a MTX-monotherapy approach, we have several options. In clinic, initiation of these other medications has often been in the form of addition rather than substitution. But what do the patients want, and how much more is the MTX adding in those cases?

Read Article
heart.jpg (keep)

Perspectives on CV safety: JAK inhibitor (Tofacitinib) and TNF inhibitors

d Janet Pope, MD, MPH, FRCPC

Safety comparisons of JAKi (tofacitinib) vs. TNFi from Oral Surveillance showed that, in patients with active RA on MTX and aged >50 years with one or more CV risk factors, that there was numerically more MACE events, malignancies, and VTE especially in higher dose.

Read Article
Cytokines & Chemokines Predict Incident MACE in RA Veterans: Dr. El Ramahi ( @MeralElRamahiMD) discusses abstract #0572 presented at the #ACR21 annual meeting. https://t.co/nM2YBuAzMh https://t.co/Pv8tVQOzol

Links:

Dr. John Cush RheumNow ( View Tweet)
Are you Aware of COPA Syndrome? Dr. Meral El Ramahi ( @MeralElRamahiMD) discusses abstract #0529 at the #ACR21 annual meeting. https://t.co/vsOvPV5JQp https://t.co/E7ugLvt5uO

Links:

Dr. John Cush RheumNow ( View Tweet)
Health Information Use by SLE Patients: Dr. Sheila Reyes ( @RHEUMarampa) discusses abstract #0880 presented at the #ACR21 annual meeting. https://t.co/48KOK413lO

Links:

Dr. John Cush RheumNow ( View Tweet)

Twin Studies on Psoriasis Microbiome: Dr. Robert Chao ( @doctorRBC) discusses abstract #0944 presented at the #ACR21 annual meeting. https://t.co/NCGkuEkued https://t.co/N03gPIqwvQ

Links:

Dr. John Cush RheumNow ( View Tweet)
Poverty and Length of Hospital Stays for Children with Lupus: Dr. Bella Mehta ( @bella_mehta) discusses abstract #0768 presented at the #ACR21 annual meeting. https://t.co/86ZTH99QN7 https://t.co/KCAkmmgmsP

Links:

Dr. John Cush RheumNow ( View Tweet)
Is it time to go back to big F2F conferences? Yes if you get VAX'd, Carded & Temp'd AND you Mask-up, Back-up and Wash-up! It might could be safe! https://t.co/Ut6LxAEmiT
Dr. John Cush RheumNow ( View Tweet)
Filgotinib (Jyseleca) was approved by European Commission approved for EU use in adults with moderately to severely active Ulcerative colitis (not responding to conventional therapy or a biologic). Rec based on Phase 2b/3 SELECTION trial. https://t.co/vMGNMKhy34

Links:

Dr. John Cush RheumNow ( View Tweet)

Improving Our Everyday RA Practice: Dr. David Liew ( @drdavidliew) discusses abstracts #0830 and #0815 presented at the #ACR21 annual meeting. https://t.co/63oTD80hrD https://t.co/iQPVYWoIuF

Links:

Dr. John Cush RheumNow ( View Tweet)
Perspectives on CV safety: JAK inhibitor (Tofacitinib) and TNF inhibitors https://t.co/yBnIsgU62y https://t.co/zT1PM08wjN

Links:

Dr. John Cush RheumNow ( View Tweet)
More severe COVID-19 outcomes in African American, Hispanic individuals with SLE https://t.co/ZHmj5wXEtS https://t.co/c88a0y2i7K

Links:

Dr. John Cush RheumNow ( View Tweet)
Treat to Target in SLE: Dr. Yuzaiful Yusof ( @Yuz6Yusof) reviews abstract #0865 presented at the #ACR21 annual meeting. https://t.co/srdhzwlvPF https://t.co/8pbb5LeFtY

Links:

Dr. John Cush RheumNow ( View Tweet)
Health Disparities: Dr. Arthur Kavanaugh discussed how a number of studies presented at the #ACR21 annual meeting are looking at the impact of socioeconomic factors and race on outcomes. https://t.co/KunXNfbaRk https://t.co/b8SgnXmrZO

Links:

Dr. John Cush RheumNow ( View Tweet)
Potpourri of Biosimilar Trials: Dr. Jonathan Kay discusses a number of biosimilar trials presented at the #ACR21 annual meeting, including abstracts #0822, #0820, #0817 and #0823. https://t.co/aQXrKKZXhb https://t.co/4Bn7rvogHY

Links:

Dr. John Cush RheumNow ( View Tweet)
Updates on New Treatments for SpA: Drs. Antoni Chan ( @synovialjoints) interviews Dr. Laura Coates discuss a number of studies related to new treatments for SpA presented at the #ACR21 annual meeting. https://t.co/mOutSekQkJ https://t.co/JG18q9PsdD

Links:

Dr. John Cush RheumNow ( View Tweet)
Best of PSA from Sunday Sessions: Dr. Rachel Tate ( @uptoTate) discusses the RheumNow PSA faculty's best PsA abstracts from Sunday sessions, including abstracts #0750 and #0944, which were presented at the #ACR21 annual meeting. https://t.co/wgMq2rsWNj https://t.co/Z2By90rBEy

Links:

Dr. John Cush RheumNow ( View Tweet)
Lipidomic Differences in PsA and RA: Dr. Pedro Castillo ( @_Castillo_Pedro) discusses abstract #0946 presented at the #ACR21 annual meeting. https://t.co/M8O1OdvFAk https://t.co/4QMgXPhLzn

Links:

Dr. John Cush RheumNow ( View Tweet)
Hydroxychloroquine Levels in Type I and 2 Lupus: Bella Mehta ( @bella_mehta) interviews Dr. Megan Clowse about abstract #0877, presented at the #ACR21 annual meeting. https://t.co/L62iO8J9QF https://t.co/Oy58jbPPts

Links:

Dr. John Cush RheumNow ( View Tweet)
Treat to Target in SLE: Dr. Yuzaiful Yusof ( @Yuz6Yusof ) reviews abstract #0865 presented at the #ACR21 annual meeting. https://t.co/THX4nLWCaR https://t.co/951HAdkONi

Links:

Dr. John Cush RheumNow ( View Tweet)
×